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beneﬁ ciaries who were enrolled in an MA-PD or a drug plan with drug deductibles, 
tiered copayments, or mailorder services in the plan beneﬁ t design were more likely 
to experience CRN.
PIH54
HEALTH CARE UTILIZATION AND COSTS AMONGST WOMEN WITH
FEMALE SEXUAL DYSFUNCTION (FSD) AND HYPOACTIVE SEXUAL
DESIRE DISORDER (HSDD)
Foley K1, Foley D2, Shah H3
1Thomson Reuters, Philadelphia, PA, USA, 2Boehringer Ingelheim Ltd, Ridgeﬁ eld, CT, USA, 
3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgeﬁ eld, CT, USA
OBJECTIVES: The health care utilization and costs among commercially insured 
women with a diagnosis of Female Sexual Dysfunction (FSD) and Hypoactive Sexual 
Desire Disorder (HSDD) in the United States. METHODS: The Thomson Reuters
Marketscan Database was used to identify women aged 18–64 with an ICD-9-CM 
coded diagnosis of FSD, including a subset with HSDD from January 1, 1998-Sep-
tember 30, 2006. A control group of women with no diagnosis of any sexual dysfunc-
tion was matched 3:1 to cases based on age, health plan and enrollment period.
Controls were assigned the index date of their matched case. Health care utilization 
and costs were examined in the year prior (“pre-period”) to and following index 
(“post-period”). RESULTS: A total of 4831 women were coded as FSD (59% as
HSDD) and matched to 14,493 controls. The FSD group had more outpatient visits
and services in both the pre- (22.2 vs. 16.2, p  0.001) and post- (25.4 vs. 17.7, p 
0.001) periods compared with their matched controls. They also consistently ﬁ lled 
more prescriptions in the pre- (14.5 vs. 11.5, p  0.001) and post- (16.2 vs. 7.2, p 
0.001) periods. Nearly identical patterns were observed in the HSDD group. These 
higher levels of utilization resulted in costs that were higher for FSD and HSDD 
women relative to their matched controls in the pre-period ($1296 and $ 1146 respec-
tively). Similar patterns of increased health care utilization were also seen in the post-
period for both FSD and HSDD patients ($1,190 and $897 respectively). The most
signiﬁ cant drivers of health care costs for both groups were outpatient medical services
(including professional visits, outpatient surgeries, and laboratory expenditures) and
total prescription medication costs. CONCLUSIONS: Women diagnosed with FSD
and HSDD use signiﬁ cantly more health care services than women without diagnosed 
sexual dysfunction. The resulting higher costs are driven by a greater use of outpatient 
services and prescription medications.
PIH56
CARESS: THE CANADIAN REGISTRY OF SYNAGIS‚ SUMMARY OF
2006–2008 RSV SEASONS
Paes B1, Reim EK2, Lanctôt KL2, Mitchell I3
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, 
ON, Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: To understand current management (utilization, compliance) with
palivizumab prophylaxis of children at high-risk of RSV infection in Canada. 
METHODS: A prospective, observational, registry of infants at high risk for RSV who
received at least one dose of palivizumab during the 2006 to 2008 RSV seasons from 
24 sites. Neonatal and demographic data were collected upon enrollment. Data on
palivizumab utilization and compliance, including outcomes related to a respiratory 
infection were collected monthly until the full course of palivizumab was completed
or at the end of the relevant RSV season. RESULTS: A total of 2910 infants were
enrolled, age two days to 47 months (mean  5.5 months). In total, 54.4% were male, 
62.2% Caucasian, average gestational age (GA) was 32.0 o 6.8 completed weeks.
2079 (71.4%) infants received palivizumab because they were premature only (i.e.
a35 completed weeks GA), 255 (8.8%) required oxygen, 288 (9.9%) had congenital 
heart disease and 288 (9.9%) were prophylaxed for other risk factors such as CNS
disorders, airway anomalies and cystic ﬁ brosis. Compliance was high; 77.8% received 
at least four injections of palivizumab between September and June each season.
Overall 12, 973 doses were given. No directly related serious adverse events were
identiﬁ ed. A total of 159 infants had 194 hospitalizations for respiratory tract infec-
tions (hospitalization rate 5.5%) and rates were highest in those with chronic lung 
disease (9.8%, p  0.006). The RSV positive hospitalization rate was only 0.96%. 
CONCLUSIONS: The RSV hospitalization rate observed in the 2006–2008 RSV
seasons was lower than that found in several published reports (range1.3%–5.3%). 
The rates of RSV hospitalization may be decreasing for various reasons such as high
compliance with palivizumab prophylaxis, variability in RSV epidemiology, hospital
admission criteria and preventive education.
MENTAL HEALTH – Clinical Outcomes Studies
PMH1
ALPRAZOLAM-RELATED DEATHS IN WEST VIRGINIA
Shah N, Smith MJ, Abate MA
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Alprazolam is a frequently prescribed benzodiazepine associated with 
abuse and misuse that can lead to fatalities. This study’s aims were to: 1) describe the 
characteristics of alprazolam-related death cases; 2) describe the comorbidities, co-
ingested drugs, and mean alprazolam concentrations of decedents; and 3) compare
characteristics between alprazolam and non alprazolam-related death cases.
METHODS: Data from all drug-related deaths in West Virginia from January 1,
2005 to November 16, 2007 were extracted from the Forensic Drug Database. Chi 
square tests compared categorical descriptive statistics between alprazolam and non-
alprazolam cases. One-way ANOVA compared mean alprazolam blood concentra-
tions based upon numbers of other ingested drugs. RESULTS: Of the 1199 drug-related 
deaths in the database, alprazolam was a contributing cause in 204 (17.0%) cases. It 
was involved in an increasing number of drug-related deaths over time. The mean age 
of alprazolam cases was 39.6 (11.2) years; most were male (66.3%) and white 
(96.0%), with the deaths ruled accidental (90.2%). There was a prescription for
alprazolam in over half the cases (52.5%); approximately one-third (33.8%) had a
history of substance abuse or cardiovascular disease. At least one other drug was a 
contributor to death in 97.5% of the alprazolam cases, with an opiate detected in 
most cases (88.7%). The mean alprazolam blood concentration was signiﬁ cantly 
higher when taken alone than when ingested with one or more drugs (p  0.001). 
More alprazolam decedents were obese (43.9%) compared to non-alprazolam dece-
dents (32.9%) (p  0.005). Alprazolam cases had a signiﬁ cantly greater average
number of drugs implicated in death (2.9  1.0) than non-alprazolam cases (2.3  1.3) 
(p  0.001). CONCLUSIONS: Alprazolam-associated deaths are a signiﬁ cant public 
health problem in West Virginia; these cases have characteristics that can differ from
other drug death cases. Certain drug combinations involving alprazolam may pose a 
greater risk for serious adverse events.
PMH2
USE OF HYPNOTICS/ANXIOLYTICS IN PATIENTS WITH MAJOR
DEPRESSIVE DISORDER: ASSOCIATIONS WITH CHRONIC PAIN, SLEEP
DISORDERS, AND ANTIDEPRESSANT SELECTION
Liu X1, Ye W2, Wohlreich M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Many patients with major depressive disorder (MDD) suffer from
chronic pain (CP) and sleep disturbances (SD). Little is known about associations
between the use of hypnotics/anxiolytics for these conditions and the use of antidepres-
sants in real-world clinical settings. This study examined the use of hypnotics and 
anxiolytics, their associations with CP and SD, and initiation of serotonin-norepineph-
rine reuptake inhibitors (duloxetine and venlafaxine XR) in a large managed-care 
population of patients with MDD. METHODS: A total of 153,913 patients who had
at least 1 diagnosis of MDD during the year 2006 were selected from a large com-
mercially insured administrative claims database. The analytic sample consisted of 
47,109 (30.6%) males and 106,804 (69.4%) females, with a mean age of 43.6 years
(SD  12.7). In accordance with ICD-9-CM, CP was deﬁ ned as any pain of the fol-
lowing 6 categories: headache, rheumatoid arthritis, osteoarthritis, low back pain, 
ﬁ bromyalgia, and neuropathic pain. Hypnotics/anxiolytics were classiﬁ ed into 3 cate-
gories: benzodiazepines (BENZ), non-benzodiazepine hypnotics (NBENZH), and non-
benzodiazepine anxiolytics (NBENZA). RESULTS: Of the 153,913 patients with 
MDD, 35.5% had CP; 5.3%, SD; and 7.3%, CP plus SD. Over the 1-year study
period, 33.1% of patients were prescribed BENZ; 16.9%, NBENZH; and 6.1%,
NBENZA. Of patients with MDD, patients also diagnosed with CP and SD were most 
frequently prescribed NBENZH, BENZ, and NBENZA (36.4%, 47.7%, 9.6%), fol-
lowed by patients with SD (30.2%, 36.7%, 6.4%), CP (18.7%, 39.9%, 7.4%), and 
MDD only (11.6%, 26.1%, 4.6%). Prior use of BENZ (OR  1.5, 95% CI  1.4–1.6), 
NBENZH (OR  1.6, 95% CI  1.5–1.7), and NBENZA (OR  1.2, 95% CI  1.1–
1.3) was signiﬁ cantly associated with initiation of duloxetine compared with venla-
faxine XR. CONCLUSIONS: Hypnotics and anxiolytics are commonly used in MDD
patients. CP and SD are associated with increased use of hypnotics and anxioloytics 
in MDD patients. Prior use of hypnotics and anxioloytics may be associated with
antidepressant selection.
PMH3
DEPRESSION: ETHNIC DIFFERENCES IN PREVALENCE, DIAGNOSIS, 
AND SYMPTOMS
Kannan H, Bolge SC, Wagner S
Consumer Health Sciences International, Princeton, NJ, USA
OBJECTIVES: To assess ethnic differences in the prevalence, physician diagnosis and 
symptomology of depression. METHODS: Data were taken from the 2008 US
National Health and Wellness Survey (NHWS), a self-reported, Internet-based study
of the disease status, attitudes, habits, and outcomes of adults age 18. Ethnic groups 
included whites, blacks, Hispanics and Asians. Respondents self reported experiencing 
depression, depression diagnosed by a physician, and experiencing the following in 
the previous month: bothered by feeling down, depressed, or hopeless; bothered by 
having little interest or pleasure in doing things. Prevalence was calculated using fre-
quency weights based on age, gender and race. Chi-square analyses were conducted 
to assess statistically signiﬁ cant differences. RESULTS: Of the 61,016 respondents,
22.2% (Projected 53.8M; 25%) reported experiencing depression within the previous 
year. There were signiﬁ cant (p  0.05) variations across ethnic groups: White  39.5M, 
25.8%; Black  4.9M, 19.8%; Hispanic  8.1M, 27.6%; Asian  1.3M, 16.1%). 
Among those who report experiencing depression, whites were most likely to be
diagnosed (77.0%) compared with 60.8% of blacks, 62.8% of Hispanics, and only
48.4% of Asians, who were least likely to be diagnosed. Among those who did not
self-report experiencing depression, 11.2% of whites, 12.8% of blacks, 13.1% of 
Hispanics, and 13.46% of Asians experienced one depression symptom and 9.6% of 
whites, 11.9% of blacks, 13.2% of Hispanics, and 12.2% of Asians experienced both
depression symptoms (p  0.05). CONCLUSIONS: While there is signiﬁ cant ethnic 
variation in prevalence of self-reported depression, there is even greater ethnic varia-
tion in diagnosis among patients experiencing depression. Also, recognition of symp-
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toms as depression is poorer among ethnic minorities than among whites. Patient and
physician education campaigns aimed at addressing the cultural stigma and percep-
tions of depression as well as available treatment options available may increase likeli-
hood of diagnosis and possibly lead to better outcomes.
PMH4
PREVALENCE OF DEPRESSION IN EUROPE: A COMPARISON OF
FIVE COUNTRIES
Narayanan S1, Potthoff P2, Guether B2
1TNS Healthcare, New York, NY, USA, 2TNS Healthcare, Munich, Bavaria, Germany
OBJECTIVES: To assess the prevalence of depression among ﬁ ve large European
nations. METHODS: TNS Healthcare’s European Healthcare Panel of individuals in
France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess 
disease burden at national level. The self-reported epidemiological data is representa-
tive of population gender and age (18–24, 25–34, 35–44, 45–54, 55–64, 65–69 yrs) 
strata in respective countries, ensured by sampling and intensive panel management.
The survey collected information on select health conditions (incl. depression; in the 
past 12-months), quality of life and health care-utilization. RESULTS: In the TNS
European Healthcare Panel, 8,665, 25,265, 19,887, 59,850 and 47,340 individuals 
completed survey in the Netherlands, Germany, Italy, France and UK respectively. 
Prevalence of Depression varied widely between these 5 nations, as follows: Nether-
lands: 9.4%, Germany: 14.6%, U.K: 14.8%, France: 17.8%, Germany: 18.8%.
Within each country, burden of Depression varied by age and gender; distribution 
among male (18–24, 25–34, 35–44, 45–54, 55–64, 65 yrs: % pts) was: the Nether-
lands: 5.1%, 6.0%, 7.0%, 7.6%, 7.3%, 5.1%; Germany: 10.9%, 9.9%, 11.2%, 
13.7%, 10.6%, 3.7%; Italy: 9.9%, 7.4%, 9.5%, 10.9%, 11.3%, 9.4%; France: 
13.7%, 12.8%, 14.4%, 14.6%, 10.9%, 6.2%; U.K: 11.8%, 12.2%, 15.8%, 18.7%,
14.0%, 7.0%; distribution among female (18–24, 25–34, 35–44, 45–54, 55–64, 65
yrs: % pts) was: the Netherlands: 5.7%, 14.4%, 13.4%, 13.3%, 10.9%, 13.8%;
Germany: 18.9%, 17.9%, 19.8%, 24.2%, 16.0%, 8.2%; Italy: 17.7%, 17.7%, 
21.1%, 24.7%, 21.3%, 12.2%; France: 25.4%, 23.4%, 23.0%, 23.7%, 19.5%, 
15.5%; UK: 24.9%, 24.8%, 26.6%, 26.2%, 19.1%, 12.8%. General Practitioners
were the primary point of diagnosis and source of treatment, even though this statistic
varied between the countries. CONCLUSIONS: Prevalence of depression appears to
be substantial in the studied European nations and peaked in the 35–55 age-group.
Females had substantially higher disease burden, amounting to as much as twice as 
their male counterparts in certain age groups.
PMH5
PATIENT ASSESSED QUALITY OF LIFE VERSUS CLINICIAN ASSESSMENT: 
A POST-HOC ANALYSIS OF A TRIAL OF ARIPIPRAZOLE IN ADOLESCENT
PATIENTS WITH SCHIZOPHRENIA
Wisniewski SR1, Whitehead R2, Ali M3, Jin N3, Kim E4, Nyilas M5, Carson WH5, Iwamoto T5, 
Mathew S2, Pikalov A2, Jing Y4
1University of Pittsburgh, Pittsburgh, PA, USA, 2Otsuka America Pharmaceutical, Inc, Rockville, 
MD, USA, 3Otsuka Pharmaceutical Development and Commercialization, Inc, Rockville, MD, 
USA, 4Bristol-Myers Squibb, Plainsboro, NJ, USA, 5Otsuka Pharmaceutical Development and 
Commercialization, Inc, Princeton, NJ, USA
OBJECTIVES: The pediatric Quality of Life Enjoyment and Satisfaction Question-
naire (PQ-LES-Q) is made up of 14 items that assess quality of life (QoL) aspects
(Total) and a 1-item overall assessment (Overall). This post-hoc analysis determined 
whether patient’s assessment in QoL correlated with improvement as determined by 
the clinical assessment (i.e. PANSS; CGI-S). METHODS: A total of 302 patients (aged 
13–17) with schizophrenia participated in a 6-week, multicenter, double-blind, ran-
domized trial. The primary measure was mean change from baseline in PANSS Total
score (LOCF). Secondary measures included CGI-S and the PQ-LES-Q Total and
Overall. Relationships between percentage of change from baseline in PQ-LES-Q. 
Total and percentage of change in PANSS and between change from baseline in PQ-
LES-Q Total and change from baseline in CGI-S score were tested by Pearson correla-
tion and trend analysis (Cochran-Mantel-Haenszel). RESULTS: Aripiprazole showed
signiﬁ cant improvements over placebo in PANSS, CGI-S, and PQ-LES-Q Overall
(week 6; p  0.05; LOCF). Strong correlation was found between all measures in 
the overall population, including PQ-LES-Q Total versus PANSS Total score and PQ-
LES-Q Overall versus CGI-S (r  0.33 and 0.29; p  0.01). Analysis by treatment 
arm showed strong correlation between change in PQ-LES-Q Total versus change in 
PANSS Total in all groups (r  0.44; p  0.011; LOCF). Correlation between change
in PQ-LES-Q Overall versus change in CGI-S was signiﬁ cant in the 10 mg/day group 
(r  0.33; p  0.001; LOCF), but not for the 30 mg/day and placebo groups (r 
0.084). Categories of CGI-S and PANSS Total improvement correlated with change
in PQ-LES-Q (p  0.001; LOCF). CONCLUSIONS: Improvements in patient-assessed 
QoL were signiﬁ cantly correlated with clinician reported outcomes in the overall
population and in individual treatment groups. Aripiprazole 10 mg/day and the com-
bined treatment group demonstrated a signiﬁ cant correlation between improvements 
in global QoL and global severity of illness.
PMH6
A COMPARATIVE REVIEW OF SAFETY, EFFICACY AND ECONOMICS OF
OFF-LABEL PRESCRIBING OF LEADING ATYPICAL ANTIPSYCHOTICS
Mittal AR
St. John’s University, Jamaica, NY, USA
OBJECTIVES: To examine the controversial practice of off-label prescribing of atypi-
cal antipsychotic drugs and to review research evidence pertaining to the economics 
of their use, safety, efﬁ cacy and appropriateness of such prescribing. METHODS: A
comprehensive review of scientiﬁ c literature published between 2001–2009, covering
all empirical studies that examined off-label prescribing of atypical antipsychotics. 
Quantitative and qualitative analyses of published secondary data for off-label uses 
of three leading atypical anti-psychotics were conducted to gain insights into preva-
lence of off-label use, costs, and mortality associated with their use. RESULTS: Twenty 
experimental and observational studies qualiﬁ ed for inclusion. Most study participants
were institutionalized elderly, Caucasian men, with Alzheimer’s disease. The newer 
atypicals accounted for more than $11 billion in annual sales and represented 90% 
of the antipsychotic market in 2005. There was a ﬁ ve-fold increase in the prescription
of these drugs particularly in children in the last decade and a half. Risperidone was
the most prescribed drug off-label. EPS, gait disturbances and weight gain were the 
most commonly cited adverse events. Elderly patients with dementia-related psychosis 
treated with atypical antipsychotics were found to be at an increased risk of adverse
events and death. CONCLUSIONS: The research evidence available to determine the
true extent and consequences of off-label prescribing of atypical antipsychotics, while 
scarce and conﬂ icting, is mostly critical of their use in children and elderly with 
dementia. Scientiﬁ c support documenting the efﬁ cacy and appropriateness of these 
drugs for treating depression and behavioral disorders of dementia is currently incon-
clusive. The high cost of these drugs may arguably offset the advantages stemming 
from their perceived lower side-effect proﬁ le.
PMH7
PATIENT ASSESSED QUALITY OF LIFE VS. CLINICIAN ASSESSMENT
IN A TRIAL OF ARIPIPRAZOLE IN PEDIATRIC PATIENTS WITH 
BIPOLAR DISORDER
Whitehead R1, Chen CF2, Kim E3, Carson WH2, Iwamoto T2, Mathew S1, Pikalov A1, Jing Y3
1Otsuka America Pharmaceutical, Inc, Rockville, MD, USA, 2Otsuka Pharmaceutical 
Development and Commercialization, Inc, Princeton, NJ, USA, 3Bristol-Myers Squibb, 
Plainsboro, NJ, USA
OBJECTIVES: The pediatric Quality of Life Enjoyment and Satisfaction Question-
naire (PQ-LES-Q) is made up of 14 items that assess aspects of quality of life (Total) 
and a 1-item overall assessment (Overall). Quality of Life measures yield information 
independent of symptom measures. This post-hoc analysis investigated correlation 
between patient’s QoL assessment and objective clinical assessment (YMRS, CGI-BP). 
METHODS: A total 296 children (age 10–17) with bipolar disorder participated in a 
4-week double-blind trial of aripiprazole (10 or 30 mg/day, ﬁ xed doses) vs. placebo 
(PBO). Completers entered a 26 week extension. Primary outcome was mean change 
on YMRS Total Score. Secondary measures included mean changes on CGI-BP
Overall, PQ-LES-Q Total (T) and the Overall item (O). RESULTS: YMRS Total and 
CGI-BP Overall improved vs. PBO with both doses of aripiprazole at week 4 and 
week 30 (p  0.05 and p  0.01 respectively, LOCF). Both aripiprazole arms improved 
on PQ-LES-Q(T) and (O); however they did not reach statistical signiﬁ cance. Observed 
Cases analysis (OC) demonstrated a correlation at week 4 and week 30 between % 
change in PQ-LES-Q(T) and % change in YMRS (r  0.18 and 0.29, respectively; 
p  0.03). When 4 week YMRS Total improvement was put into categories (20%; 
20–30%; 30–50%; 50% reduction), % change in mean PQ-LES-Q(T) was 1.7, 2.3, 
12.5, & 10.4 per category (trend analysis p  0.007; regression p  0.01; OC). At 30 
weeks % change in mean PQ-LES-Q(T) was 3.3, NA, 2.6, 16.6 (p  0.02; Linear
regression p  0.02; OC). When CGI-BP Overall was put into 4 categories ( 0; 1; 
2; a3 point change) at 4 weeks, % change in mean PQ-LES-Q(O) was 0.02, 0.15, 
0.27, 0.43 per category (trend analysis p  0.05; OC) and at 30 weeks, % change in
mean PQ-LES-Q(O) was 1, 0, 0.63, 0.64 (p  0.02; OC). CONCLUSIONS: In this
trial of pediatric patients with BP there was positive correlation between patient-
assessed QoL measures and clinician-based assessment.
PMH8
GROWTH AND DIFFUSION OF ANTIPSYCHOTIC MEDICINES FOR
LABELED AND OFF-LABELED USES, 1994–2007
Alexander GC1, Gallagher SA1, Mascola A2, Moloney R1, Stafford R2
1University of Chicago, Chicago, IL, USA, 2Stanford University, Stanford, CA, USA
OBJECTIVES: Antipsychotic drugs are widely used and costly. Little is known 
about how this has varied based on clinical applications and levels of evidence. 
METHODS: We used the IMS Health National Disease and Therapeutic Index to 
describe typical and atypical antipsychotic use from 1994 through 2007. We linked
this nationally representative cross-sectional data from outpatient physician practices 
to levels of evidence and FDA approval status from the FDA and the Drugdex
drug compendium. We obtained promotional and prescription expenditures from
IMS Health Integrated Promotional Services and the National Prescription Audit.
RESULTS: Preliminary results suggest aggregate annual antipsychotic use increased 
262% from 8 million physician visits (1994) to 21 million (2006), then declined to
19 million (2007). The market share of typical antipsychotics decreased from 86%
to 8% over this time period. Large increases in antipsychotic use occurred among 
individuals 18–64 (234%) and 18 years of age (559%). Increases were more modest
among those 65 years of age or older (131%). Antipsychotic use for schizophrenia
